SEK 37.65
(2.45%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 584 Thousand EUR | -28.52% |
2022 | 817 Thousand EUR | 0.0% |
2021 | - EUR | -100.0% |
2020 | 86 Thousand EUR | -96.1% |
2019 | 2.2 Million EUR | 0.0% |
2018 | - EUR | 0.0% |
2017 | - EUR | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 486 Thousand EUR | 0.0% |
2024 Q2 | - EUR | 0.0% |
2023 Q1 | 740 Thousand EUR | -9.42% |
2023 Q3 | 628 Thousand EUR | -8.59% |
2023 FY | 584 Thousand EUR | -28.52% |
2023 Q4 | 584 Thousand EUR | -7.01% |
2023 Q2 | 687 Thousand EUR | -7.16% |
2022 Q1 | - EUR | 0.0% |
2022 Q2 | - EUR | 0.0% |
2022 Q3 | - EUR | 0.0% |
2022 Q4 | 817 Thousand EUR | 0.0% |
2022 FY | 817 Thousand EUR | 0.0% |
2021 Q3 | 4000.00 EUR | -87.1% |
2021 Q1 | 57 Thousand EUR | -33.72% |
2021 Q2 | 31 Thousand EUR | -45.61% |
2021 FY | - EUR | -100.0% |
2021 Q4 | - EUR | -100.0% |
2020 Q1 | - EUR | -100.0% |
2020 Q3 | - EUR | -100.0% |
2020 Q2 | 2.54 Million EUR | 0.0% |
2020 FY | 86 Thousand EUR | -96.1% |
2020 Q4 | 86 Thousand EUR | 0.0% |
2019 FY | 2.2 Million EUR | 0.0% |
2019 Q4 | 2.2 Million EUR | 0.0% |
2018 FY | - EUR | 0.0% |
2017 FY | - EUR | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Acarix AB (publ) | - SEK | -Infinity% |
ADDvise Group AB (publ) | 1.45 Billion SEK | 99.96% |
ADDvise Group AB (publ) | 1.45 Billion SEK | 99.96% |
Arcoma AB | 1.92 Million SEK | 69.694% |
Bactiguard Holding AB (publ) | 42.3 Million SEK | 98.62% |
BICO Group AB (publ) | 1.75 Billion SEK | 99.967% |
Boule Diagnostics AB (publ) | 57.7 Million SEK | 98.988% |
CellaVision AB (publ) | 28.66 Million SEK | 97.963% |
Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | -161.883% |
Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
C-Rad AB (publ) | 1.75 Million SEK | 66.686% |
Duearity AB (publ) | 2.94 Million SEK | 80.136% |
Dignitana AB (publ) | 6.07 Million SEK | 90.39% |
Episurf Medical AB (publ) | 2.3 Million SEK | 74.609% |
Getinge AB (publ) | 3.9 Billion SEK | 99.985% |
Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 90.807% |
Iconovo AB (publ) | 4.9 Million SEK | 88.098% |
Integrum AB (publ) | 4.84 Million SEK | 87.945% |
Luxbright AB (publ) | 206.02 Thousand SEK | -183.462% |
Mentice AB (publ) | 2.14 Million SEK | 72.761% |
OssDsign AB (publ) | 214 Thousand SEK | -172.897% |
Paxman AB (publ) | 2.53 Million SEK | 76.935% |
Promimic AB (publ) | - SEK | -Infinity% |
Qlife Holding AB (publ) | 3 Million SEK | 80.559% |
SciBase Holding AB (publ) | 4.17 Million SEK | 86.025% |
ScandiDos AB (publ) | - SEK | -Infinity% |
Sectra AB (publ) | 19.2 Million SEK | 96.959% |
Sedana Medical AB (publ) | 1.01 Million SEK | 42.292% |
Senzime AB (publ) | 8.57 Million SEK | 93.192% |
SpectraCure AB (publ) | 4.39 Million SEK | 86.718% |
Stille AB | 38.06 Million SEK | 98.466% |
Vitrolife AB (publ) | 1.87 Billion SEK | 99.969% |
Xvivo Perfusion AB (publ) | 21.16 Million SEK | 97.241% |